Physician
Radiation Oncology
Dr. Andrew Raubitschek, MD
|
|
Give Review
Andrew Raubitschek is an expert in the field of Radiation Oncology. He graduated from University of California San Francisco School of Medicine. University of California San Francisco School of Medicine is a one of the best medicals schools. University of California San Francisco School of Medicine has a rank of 3 in research and a 3 in primary care Andrew Raubitschek is a published MD as well. He has 101 publications published. The latest was: Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients. Andrew Raubitschek is registered with Medicare and accepts Medicare payments.
Publications
- Autologous transplantation for transformed non-hodgkin lymphoma using an yttrium-90 ibritumomab tiuxetan conditioning regimen.
- Functional Imaging of Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Using 64Cu-DOTA-Trastuzumab PET.
- Intracellular processing of immunostimulatory CpG-siRNA: Toll-like receptor 9 facilitates siRNA dicing and endosomal escape.
- Serial Diffusion MRI to Monitor and Model Treatment Response of the Targeted Nanotherapy CRLX101.
- TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo.
- A series of anti-CEA/anti-DOTA bispecific antibody formats evaluated for pre-targeting: comparison of tumor uptake and blood clearance.
- Intracerebral CpG Immunotherapy with Carbon Nanotubes Abrogates Growth of Subcutaneous Melanomas in Mice.
- Mammalian expression and hollow fiber bioreactor production of recombinant anti-CEA diabody and minibody for clinical applications.
- An improved method for conjugating monoclonal antibodies with N-hydroxysulfosuccinimidyl DOTA.
- Metabolism and renal clearance of 111In-labeled DOTA-conjugated antibody fragments.
- Tumor targeting of radiometal labeled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments.
- Numerical selection of optimal tumor imaging agents with application to engineered antibodies.
- A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignanc...
- Phase I/II 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin''s lymphoma.
- Human T lymphocyte genetic modification with naked DNA.
- High-resolution microPET imaging of carcinoembryonic antigen-positive xenografts by using a copper-64-labeled engineered antibody fragment.
- Truncation of blood curves to enhance imaging and therapy with monoclonal antibodies.
- Biodistribution and radioimmunotherapy of human breast cancer xenografts with radiometal-labeled DOTA conjugated anti-HER2/neu antibody 4D5.
- Evaluating changes in stable chromosomal translocation frequency in patients receiving radioimmunotherapy.
- Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma.
- Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with zevalin, a 90Y-labeled anti-CD20 monoclonal antibody.
- Initial clinical experience evaluating Yttrium-90-chimeric T84.66 anticarcinoembryonic antigen antibody and autologous hematopoietic stem cell support in patients with...
- A method for patient-specific absorbed dose estimation for internal beta emitters.
- A radionuclide therapy treatment planning and dose estimation system.
- Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapy.
- A chimeric anti-CEA antibody with heavy interchain disulfide bonds deleted: molecular characterization and biodistributions in normal and tumor bearing mice.
- Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
- Dose escalation trial of indium-111-labeled anti-carcinoembryonic antigen chimeric monoclonal antibody (chimeric T84.66) in presurgical colorectal cancer patients.
- CD20 is a molecular target for scFvFc:zeta receptor redirected T cells: implications for cellular immunotherapy of CD20+ malignancy.
- Monte Carlo-assisted voxel source kernel method (MAVSK) for internal beta dosimetry.
- Biodistribution of 111In- and 90Y-labeled DOTA and maleimidocysteineamido-DOTA conjugated to chimeric anticarcinoembryonic antigen antibody in xenograft-bearing nude m...
- Estimating residence times and their associated errors in patient absorbed-dose calculation.
- Pharmacokinetic modeling and absorbed dose estimation for chimeric anti-CEA antibody in humans.
- Clinical evaluation of indium-111-labeled chimeric anti-CEA monoclonal antibody.
- Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.
- A CT assisted method for absolute quantitation of internal radioactivity.
- Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies.
- Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.
- On the correction for radioactive decay in pharmacokinetic modeling.
- Pharmacokinetics and bioactivity of 1,4,7,10-tetra-azacylododecane off',N'',N'''-tetraacetic acid (DOTA)-bismuth-conjugated anti-Tac antibody for alpha-emitter (212Bi)...
- Modeling of tumor uptake to determine the time-dose-fractionation effect in radioimmunotherapy.
- Continuous infusion chemotherapy as a radiation-enhancing agent for yttrium-90-radiolabeled monoclonal antibody therapy of a human tumor xenograft.
- A facile, water-soluble method for modification of proteins with DOTA. Use of elevated temperature and optimized pH to achieve high specific activity and high chelate ...
- gamma-Interferon administration after 90yttrium radiolabeled antibody therapy: survival and hematopoietic toxicity studies.
- Dosimetric considerations in treating mediastinal disease with mantle fields: characterization of the dose under mantle blocks.
- Characterization of human hybridomas secreting antibody to tetanus toxoid.
- Production of human monoclonal antibody in mouse ascites.
- Human interleukin 2 can promote the growth and differentiation of single hapten-specific B cells in the presence of specific antigen.
- Rescue of human monoclonal antibody production from an EBV-transformed B cell line by fusion to a human-mouse hybridoma.
- Expression in COS cells of a mouse-human chimaeric B72.3 antibody.
- Purified interleukin-2 induces proliferation of fresh human lymphocytes in the absence of exogenous stimuli.
- Receptor-mediated endocytosis of human transferrin and its cell surface receptor.
- Human monoclonal antibodies against group A red blood cells.
- Characterization and biodistribution of recombinant and recombinant/chimeric constructs of monoclonal antibody B72.3.
- Studies concerning the effect of external irradiation on localization of radiolabeled monoclonal antibody B72.3 to human colon carcinoma xenografts.
- The never-ending controversies in Hodgkin's disease.
- Comparative biodistributions of yttrium- and indium-labeled monoclonal antibody B72.3 in athymic mice bearing human colon carcinoma xenografts.
- Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: critical factors in determining in vivo survival and orga...
- Comparison of bone marrow dosimetry and toxic effect of high dose 131I-labeled monoclonal antibodies administered to man.
- Human monoclonal antibodies that recognize conserved epitopes in the core-lipid A region of lipopolysaccharides.
- Minimal long-term cardiopulmonary dysfunction following treatment for Hodgkin's disease.
- A staging of lymphomas: practical thoughts on impractical practices.
- The emerging biology of modern radiation oncology.
- Potential for artifacts in monitoring for the detection of tumor associated antigens (TAG-72 and CEA) in serum from patients undergoing MAb-based diagnostic and therap...
- An isocentric chair for the simulation and treatment of radiation therapy patients.
- Radiation therapy versus combination chemotherapy in the treatment of early-stage Hodgkin's disease: seven-year results of a prospective randomized trial.
- Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy.
- Survivors of Hodgkin's disease: prevention of sequelae.
- Potential artifact for the increase of tumor associated antigens in serum samples from patients injected with monoclonal antibodies.
- Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting.
- A pilot study of the combination of interleukin-2-based immunotherapy and radiation therapy.
- Breast-tumor xenograft targeting and therapy studies using radiolabeled chimeric anti-cea monoclonal-antibody t84.66.
- Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.
- Multimerization of a chimeric anti-CD20 single-chain Fv-Fc fusion protein is mediated through variable domain exchange.
- Reduction of kidney uptake in radiometal labeled peptide linkers conjugated to recombinant antibody fragments. Site-specific conjugation of DOTA-peptides to a Cys-diab...
- The two types of correction of absorbed dose estimates for internal emitters.
- Vinyl sulfone bifunctional derivatives of DOTA allow sulfhydryl- or amino-directed coupling to antibodies. Conjugates retain immunoreactivity and have similar biodistr...
- Covalent disulfide-linked anti-CEA diabody allows site-specific conjugation and radiolabeling for tumor targeting applications.
- A Phase I trial of 90Y-anti-carcinoembryonic antigen chimeric T84.66 radioimmunotherapy with 5-fluorouracil in patients with metastatic colorectal cancer.
- 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice.
- Characterization of engineered anti-p185HER-2 (scFv-CH3)2 antibody fragments (minibodies) for tumor targeting.
- Humanization of the anti-CEA T84.66 antibody based on crystal structure data.
- Pilot trial evaluating an 123I-labeled 80-kilodalton engineered anticarcinoembryonic antigen antibody fragment (cT84.66 minibody) in patients with colorectal cancer.
- Optimizing radiolabeled engineered anti-p185HER2 antibody fragments for in vivo imaging.
- A phase I trial of (90)Y-DOTA-anti-CEA chimeric T84.66 (cT84.66) radioimmunotherapy in patients with metastatic CEA-producing malignancies.
- Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.
- Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy.
- Targeting, imaging, and therapy using a humanized antiprostate stem cell antigen (PSCA) antibody.
- Phase II trial of a transplantation regimen of yttrium-90 ibritumomab tiuxetan and high-dose chemotherapy in patients with non-Hodgkin's lymphoma.
- Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
- Rapid and efficient production of radiolabeled antibody conjugates using vacuum diafiltration guided by mathematical modeling.
- Recombinant anti-CD20 antibody fragments for small-animal PET imaging of B-cell lymphomas.
- Site-specific conjugation of monodispersed DOTA-PEGn to a thiolated diabody reveals the effect of increasing peg size on kidney clearance and tumor uptake with improve...
- Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
- ImmunoPET imaging of B-cell lymphoma using 124I-anti-CD20 scFv dimers (diabodies).
- Matched-Cohort Analysis of Autologous Hematopoietic Cell Transplantation with Radioimmunotherapy versus Total Body Irradiation-Based Conditioning for Poor-Risk Diffuse...
- In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses.
- A pretherapy biodistribution and dosimetry study of indium-111-radiolabeled trastuzumab in patients with human epidermal growth factor receptor 2-overexpressing breast...
- Monodispersed DOTA-PEG-conjugated anti-TAG-72 diabody has low kidney uptake and high tumor-to-blood ratios resulting in improved 64Cu PET.
- Preclinical results of camptothecin-polymer conjugate (IT-101) in multiple human lymphoma xenograft models.
Schools
University of California At San Francisco
Stanford University Medical Center
Doctors Specialties
- Radiation Oncology
Accepted Insurances
Education
-
Stanford University -
University of California San Francisco School of Medicine
Hospital
-
City of Hope's Helford Clinical Research Hospital
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1407941289 |
| Last Name Of The Provider | RAUBITSCHEK |
| First Name Of The Provider | ANDREW |
| View All |
Similar Doctors
|
Dr. Yi-Jen Chen, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Richard D. Pezner, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sagus Sampath, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Eric H. Radany, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey Y. Wong, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Daniel H. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Matthew D. Hall, MD |
|
|
Dr. Benjamin L. Cahan, MD |
|
|
Dr. Ji H. Kim, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Khanh H. Nguyen, MD |